A superantigen-based MHC class II-targeted cancer immunotherapy for the treatment of acute myeloid leukemia.

Blood Cancer J · 2025 · PMC12623995 · PMID 41249828

Europe PMC DOI

hedged sentence

0.0643

closest p · 1.3× alpha

0.0643

boldest claim

The sentences

did not reach statistical significanceP = 0.0643so close (0.05 < p ≤ 0.1)

Secondary observations were that CD8+ depletion by itself accelerated AML disease progression ( P = 0.0068, N = 7–10), whereas there was a similar trend for CD4+ depletion that did not reach statistical significance ( P = 0.0643, N = 7–10).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.